Patent: 8,404,813
✉ Email this page to a colleague
Summary for Patent: 8,404,813
| Title: | Engineered anti-IL-23P19 antibodies |
| Abstract: | Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. |
| Inventor(s): | Presta Leonard G. |
| Assignee: | Merck Sharp & Dohme Corp. |
| Application Number: | US13031544 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,404,813
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ILUMYA | tildrakizumab-asmn | Injection | 761067 | March 20, 2018 | 8,404,813 | 2031-02-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,404,813
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200906224 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2008103432 | ⤷ Start Trial |
| United States of America | 2010272731 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
